Rapamycin‐based graft‐versus‐host disease prophylaxis increases the immunosuppressivity of myeloid‐derived suppressor cells without affecting T cells and anti‐tumor cytotoxicity

The immunosuppressant rapamycin (RAPA) inhibits mammalian target of rapamycin (mTOR) functions and is applied after allogeneic bone marrow transplantation (BMT) to attenuate the development of graft‐versus‐host disease (GVHD), although the cellular targets of RAPA treatment are not well defined. All...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheurer, J., Reisser, T., Leithäuser, F., Messmann, J. J., Holzmann, K., Debatin, K.‐M., Strauss, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670162/
https://www.ncbi.nlm.nih.gov/pubmed/32681646
http://dx.doi.org/10.1111/cei.13496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670162/
https://www.ncbi.nlm.nih.gov/pubmed/32681646
http://dx.doi.org/10.1111/cei.13496

Ejemplares similares